Overview

The Ending the HIV Epidemic (EHE) initiative aims to reduce new HIV infections in the U.S. by 90% by 2030. This aim will be achieved by equitably and collaboratively delivering care and focusing resources on communities most affected by HIV, including those in Southern and rural areas. Join Dr. Charles Vega, Health Sciences Clinical Professor at UC Irvine Department of Family Medicine, and Dr. Leandro Mena, Chair and Professor of the Department of Population Health Science at University of Mississippi, and Director of the Center for HIV/AIDS Research, as they discuss how to provide culturally competent and collaborative care using the four EHE strategies: diagnose, treat, prevent, and respond. 

Learning Objectives

  • Review the impact of HIV on populations in the South and in rural areas
  • Describe programs aimed at developing a model of culturally competent HIV care 
  • Discuss challenges in identifying and managing HIV in rural areas
  • Outline resources available for primary care clinicians to help in the uptake of HIV-related services across prevention, screening, treatment, and specialty care
     

     

Faculty

Charles Vega, MD, FAAFP

Health Sciences Clinical Professor
UC Irvine Department of Family Medicine
Assistant Dean for Culture and Community Education
Executive Director, UC Irvine Program in Medical Education for the Latino Community
UC Irvine School of Medicine
Irvine, CA 

Leandro Mena, MD, MPH

Founding Chair and Professor, Department of Population Health Science, University of Mississippi Medical Center John D. Bower School of Population Health; 
Professor of Medicine, Division of Infectious Diseases
Director, Center for HIV/AIDS Research, 
Education and Policy at the Myrlie Evers-Williams Institute for the Elimination of Health Disparities
the STD Medical Director for the State of Mississippi
Let’s Stop HIV Together Clinical Ambassador 

Disclosures

The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.

Charles Vega, MD, FAAFP: No relevant financial relationships disclosed. 

Leandro Mena, MD, MPH: No relevant financial relationships disclosed. 

 

Non-faculty contributors involved in the planning, development, editing, and review of the content have disclosed no relevant financial relationships. 

CME/CE Information

AMA PRA Category 1 Credits

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and CDC’s Let’s Stop HIV Together (Together) National Partnerships Team (NPT). Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians. 


Designation Statement

Pri-Med Institute designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Fine Print

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients. Data, indications, and guidelines presented in this activity are current as of the activity release date and they are subject to change as new information is published.

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.